Yes—reports of 42 kidney-related side effects linked three breast cancer drugs to problems ranging from harmless blood test rises to kidney injury. The study reviewed French drug safety reports from 2016 to January 2024. It focused on palbociclib, abemaciclib, and ribociclib, drugs used for advanced breast cancer. These drugs can raise Creatinine, a blood marker used to check kidney function. Sometimes, this happens because they change how kidneys move the marker into urine. That can raise the number without actual kidney damage. But not every rise was harmless. Only one report described a rise without true loss of kidney function. Seventeen cases involved kidney failure with dehydration, meaning too little fluid in the body. These were mostly linked to abemaciclib and digestive side effects. Another 24 cases involved kidney failure without dehydration. In some, kidney tissue tests confirmed damage or inflammation. Most cases were serious and required a hospital stay. Three needed treatment to take over the kidneys’ filtering work. The cancer drug was stopped in 85% of cases. Most had a favorable outcome. These were reports of suspected side effects, not a study of everyone taking these drugs. They cannot show how common kidney injury is or rank the drugs’ risks. For BioSocial members, the takeaway is that one number needs context. The authors highlighted Cystatin C, another blood marker, to help assess kidney filtering. Tracking test dates, medication changes, and symptoms alongside bloodwork can make community comparisons more useful. A higher Creatinine result alone does not explain why it changed. What changes have you noticed in your kidney blood tests during cancer treatment, and what other results helped you understand them?